Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical improvementclinical worseningdeathsPCR-negative conversion
proton pump inhibitors (PPI)3- OBS 2.71 [1.17; 6.30], 1 study, I2=0%
statistically significant harm
OBS 2.76 [1.51; 5.06], 2 studies, I2=0%
statistically significant harm
-
alpha lipoic acid1-- 0.17 [0.02; 1.44], 1 RCT, I2=0%
inconclusive result
-
famotidine1-- OBS 1.64 [1.14; 2.36], 1 study, I2=0%
statistically significant harm
-
acetylcysteine0----
aviptadil0----
bevacizumab0----
bismuth0----
BLD-2660 (calpain inhibitor)0----
calcium channel blocker0----
camostat mesilate0----
continuous positive airway pressure (CPAP)0----
cytokine adsorption0----
diammonium glycyrrhizinate0----
dipyridamol0----
DPP-4 inhibitor0----
enoxaparin0----
kinin-kallikrein inhibitors0----
levamisole0----
metformin0----
natural killer (NK) cells0----
nicotin0----
nitric oxide (gas Inhalation or releasing solution)0----
ozonated autohemotherapy0----
pamrevlumab0----
povidone-iodine0----
PUL-042 inhalation solution0----
radiotherapy0----
selinexor0----
statins0----
stem cells0----
tradipitant0----
tranilast0----